- Poster presentation
- Open Access
In vivo analysis of GenePro, a lentivral therapeutic vaccine
BMC Infectious Diseases volume 14, Article number: P2 (2014)
Despite advances in HIV commercial therapies, including fixed-dose combinations, unprecedented proportions of HIV patients remain without therapeutic options due to lack of access to treatment and epidemiologically significant proportions of multi-class drug resistance that are driving morbidity levels in both developed and resource-poor settings. The need to emphasize the development of therapeutic options with the potential to abrogate these correlating trends are receiving insufficient dedication of resources, as new clinical strategies do not address these enduring disparities. GenePro, a therapeutic vaccine candidate, has shown preclinical efficacy via publicly sponsored research that demonstrates the potential to address a current therapeutic issue.
Materials and methods
The GenePro therapeutic construct includes strong lentiviral promoter and 7 out of 9 HIV genes: Gag, pol, tat, rev, vpu, env and nef. In a preclinical study, kinetic analyses on splenocytes of BALB/c mice that were immunized by a single injection with a GenePro were performed. IFN-gamma-ELISPOT and multiparametric FACS analysis were conducted to characterize the induced CMI response. Animals immunized with a single high dose of GenePro were monitored longitudinally for vaccine-induced IR using multiparametric flow cytometry-based assays.
Comprehensive analysis demonstrated the capacity of a single high dose of HIV DNA vaccine alone to induce long-lasting and polyfunctional T-cell responses in the nonhuman primate model. In preclinical studies, GenePro has been found to generate the HIV-specific memory cells found in elite controllers and reconstitution of the immune system. The TriGrid delivery system increases DNA delivery efficiency by up to 1,000 fold. This approach has less toxicity and no drug resistance and may allow for STIs from ART.
Data from initial investigations of GenePro indicate improvements in immune response and generation of HIV-specific memory cells that induced immune responses by altered HIV DNA constructs, which synthetically mimic virologic responses of elite controllers. Advancement of GenePro into human studies will serve as a hallmark in continuing commercial efforts to discover a universal address for the global AIDS crisis.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Selbovitz, M., Miller, D. In vivo analysis of GenePro, a lentivral therapeutic vaccine. BMC Infect Dis 14 (Suppl 2), P2 (2014). https://doi.org/10.1186/1471-2334-14-S2-P2
- Therapeutic Vaccine
- Single High Dose
- Nonhuman Primate Model
- Elite Controller
- Preclinical Efficacy